---
schema_version: "secwatch.filing_event.v1"
accession: "0001662774-24-000004"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:38.895695+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline

## Summary
- Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.
- Net loss $27.7M ($0.64/share) includes $17.1M goodwill impairment; R&D $4.2M, G&A $4.7M.
- Phase 3 NEAT enrolled 7 patients; topline results expected Q4 2025; NDA/MAA in 2026 if positive.
- FDA Fast Track for EryDex in A-T; diagnosed U.S. patients estimated at ~4,600 (up from ~3,400).
- Planning DMD proof-of-concept study in 2025; evaluating partnerships for ex-U.S. rights.

## SEC filing metadata
- accession: 0001662774-24-000004
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000166277424000004/0001662774-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000166277424000004/qncx-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001662774-24-000004
- JSON: https://secwatch.observer/filing/0001662774-24-000004.json
- Plain text: https://secwatch.observer/filing/0001662774-24-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.